RET and pheochromocytoma: The current consensus as outlined in the 2015 Revised American Thyroid Association Guidelines for the Management of MTC is that FMTC is not a distinct clinical entity, but rather a variant of MEN2A exhibiting a phenotype that presents with only MTC, without pHPT or pheochromocytoma [15].